$OGEN Cashflow Statement | Understand Stock

$OGEN

$0.37 +$0.00 (0.0%) After hours

$OGEN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Write off of in process research and development (IPR&D)
Depreciation and amortization
Loss on sale of fixed assets, net
Amortization of debt discount and closing costs
Stock-based compensation expense
Stock-based compensation recapture expense
Common stock for services rendered
Changes in operating assets and liabilities:
Other receivables
Prepaid expenses and other current assets
Prepaid research and development expense
Operating lease right of use assets
Accounts payable and accrued expenses
Change in operating lease liabilities
Net cash used in operating activities
Proceeds from sale of property and equipment
Cash paid for IPR&D
Purchase of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Borrowings on short-term notes payable
Payments on short-term notes payable
Redemption of Series C Preferred stock
Proceeds from issuance of common stock for stock option exercise
Proceeds from issuance of common stock for warrant exercise
Net proceeds from issuance of preferred stock and warrants
Net proceeds from issuance of common stock
Net cash provided by financing activities

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of year
Supplemental disclosure of cash flow information:
Interest paid
Borrowings under short term notes payable for prepaid insurance
Issuance of Series F Preferred stock for IPR&D
Value of Series A preferred stock converted into common stock
Value of Series B preferred stock converted into common stock
Par Value of common stock issued in connection with Series A Preferred Stock Conversion
Par Value of common stock issued in connection with Series B Preferred Stock Conversion
Stock dividend on Series C preferred stock

Comments